18,705 Shares in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Purchased by B. Metzler seel. Sohn & Co. Holding AG

B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) during the third quarter, HoldingsChannel.com reports. The firm acquired 18,705 shares of the biotechnology company’s stock, valued at approximately $362,000.

Several other institutional investors have also modified their holdings of ARWR. Vanguard Group Inc. raised its holdings in Arrowhead Pharmaceuticals by 16.2% during the 1st quarter. Vanguard Group Inc. now owns 12,404,050 shares of the biotechnology company’s stock valued at $354,756,000 after buying an additional 1,731,974 shares during the period. Squarepoint Ops LLC purchased a new stake in shares of Arrowhead Pharmaceuticals in the second quarter valued at $9,976,000. Avoro Capital Advisors LLC lifted its holdings in shares of Arrowhead Pharmaceuticals by 3.9% in the 2nd quarter. Avoro Capital Advisors LLC now owns 8,888,888 shares of the biotechnology company’s stock worth $231,022,000 after acquiring an additional 333,333 shares during the last quarter. Assenagon Asset Management S.A. boosted its stake in shares of Arrowhead Pharmaceuticals by 232.5% during the 3rd quarter. Assenagon Asset Management S.A. now owns 293,083 shares of the biotechnology company’s stock worth $5,677,000 after purchasing an additional 204,933 shares during the period. Finally, Millennium Management LLC boosted its stake in shares of Arrowhead Pharmaceuticals by 61.9% during the 2nd quarter. Millennium Management LLC now owns 529,251 shares of the biotechnology company’s stock worth $13,755,000 after purchasing an additional 202,280 shares during the period. 62.61% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Piper Sandler reissued an “overweight” rating and issued a $62.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, October 8th. StockNews.com upgraded Arrowhead Pharmaceuticals to a “sell” rating in a report on Tuesday, November 12th. Royal Bank of Canada reiterated an “outperform” rating and issued a $42.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Thursday, September 26th. Cantor Fitzgerald reissued an “overweight” rating on shares of Arrowhead Pharmaceuticals in a research note on Monday, September 9th. Finally, B. Riley reaffirmed a “buy” rating and issued a $55.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 12th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, Arrowhead Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $45.33.

Arrowhead Pharmaceuticals Price Performance

Shares of Arrowhead Pharmaceuticals stock opened at $18.54 on Monday. Arrowhead Pharmaceuticals, Inc. has a 1 year low of $17.05 and a 1 year high of $39.83. The stock has a market cap of $2.30 billion, a price-to-earnings ratio of -3.97 and a beta of 0.93. The firm’s 50-day moving average is $19.86 and its two-hundred day moving average is $23.21.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.